Lundbeck said South Korea’s drug regulator granted marketing authorization for Vyepti, its migraine preventive for adults, supported by phase 3 SUNRISE trial data.

Danish drugmaker Lundbeck said South Korea’s Ministry of Food and Drug Safety has granted marketing authorization for Vyepti, or eptinezumab, for the preventive treatment of migraine in adults.

The company said the approval was supported by phase 3 SUNRISE trial data. Reuters also reported the authorization on May 26, 2026.

The decision gives Lundbeck a new market for Vyepti in Asia and broadens the drug’s regulatory footprint beyond its existing approvals.

Lundbeck did not provide commercial launch timing in the release. It also did not disclose pricing or other rollout details for South Korea.

The approval is the latest regulatory step for a migraine drug that Lundbeck is positioning as part of its broader neuroscience portfolio.

Revision note

Initial automated publication.